MedDataX Logo

Safety and Efficacy Study of Bee Venom to Treat Knee Osteoarthritis

NCT ID: NCT00253942

Last Updated: 2005-11-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study wishes to determine if the use of injectable bee venom is a safe and effective treatment for persons with mild to moderate knee Osteoarthritis and would result in decreased report of pain and discomfort, increased function during daily activities, decrease use of analgesic meds, and improvement in walking and climbing steps. We will be using histamine as a control. 40 subjects will be enrolled in a 3:1 allocation ratio between bee venom and histamine. Each injection of bee venom dosage will consist of 100 micrograms of dried bee venom in 0.1 ml. of 0.5% preservative free Xylocaine. The histamine dosage will consist of .0025 milligrams of histamine in 0.5% preservative free Xylocaine. Subjects will visit the study center for 14 visits over an 18 week span. The clinical hypothesis is that bee venom is an effective treatment for Osteoarthritis and will reduce pain and discomfort, increase range of motion, increase daily function, decrease walking and stair climbing time, and decrease the need of analgesic medication for a period of time beyond treatment (after the study has concluded.) The clinical safety hypothesis is that for persons not allergic to bee venom (patients allergic will not be allowed to enter into the study) the side effects will be small. The most common side effects for bee venom and histamine will be redness and itchiness which will be tolerable and safe.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Persons With Mild to Moderate Knee Osteoarthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Injecting bee venom as a treatment for OA

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Meet clinical criteria for Osteoarthritis in one knee
* Morning stiffness less than 30 minutes duration
* VAS pain level of 4 to 8 on a 0 to 10 scale when walking
* Older than 35 years of age
* On a stable dose of medication or none at all due to intolerance
* Ability to tolerate Acetaminophen as their only pain medication for the entire study
* Ability to read, understand, and give informed consent and sign the informed consent form

Exclusion Criteria

* Allergy to bee venom or histamine
* Allergy to Lidocaine
* Any type of inflammatory arthritis such as RA, SLE, Psoriatic
* Fibromyalgia or any pain problem that requires the use of pain medication or anti-inflammatory
* Depression or any condition that interferes with memory or critical analysis
* History of prolotherapy, bee venom therapy, or injection of hyaluronic acid or cortisone within the last 3 months
* Osteoarthritis of the hip, ankle, or any condition that interferes with walking 50 ft. or up and down stairs
* Elevated CRP, SED rate
* Recent injury to the knee which is causing pain or functional problems
* Any previous invasive procedure on the study knee
* Inability to understand the informed consent form or refusal to sign it
* Cardiac disease interfering with ability to get epinephrine
* VAS pain level greater than 8 on a 0 to 10 scale when walking
* Inability to stop anti-inflammatory medication for the entire study and use only Acetaminophen
* Taking beta blockers
* Taking chronic anti-histamines
Minimum Eligible Age

35 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Kochan Institute for Healing Arts Research

UNKNOWN

Sponsor Role collaborator

Rheumatology Therapeutics Medical Center

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boris Ratiner, MD

Role: PRINCIPAL_INVESTIGATOR

Medical Director of Rheumatology Therapeutics Medical Center

Andrew Kochan, MD

Role: PRINCIPAL_INVESTIGATOR

Medical Director of Kochan Institute for Healing Arts Research

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kochan Institute for Healing Arts Research

Encino, California, United States

Site Status RECRUITING

Rheumatology Therapeutics Medical Center

Tarzana, California, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ray Seipel, MA

Role: primary

Phil Sheng, BS

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

OABVTKNEE-001

Identifier Type: -

Identifier Source: org_study_id